The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Published version of a preprint
Abstract
The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway. Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clinical efficacy in patients with melanoma. However, the majority of responses are transient, and resistance is often associated with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway. Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors. SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRAS, or KRAS and induces tumor regressions in xenograft models at tolerated doses. Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor–resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors. These data support the clinical development of ERK inhibitors for tumors refractory to MAPK inhibitors. Significance: BRAF and MEK inhibitors have activity in MAPK-dependent cancers with BRAF or RAS mutations. However, resistance is associated with pathway alterations resulting in phospho-ERK reactivation. Here, we describe a novel ERK1/2 kinase inhibitor that has antitumor activity in MAPK inhibitor-naïve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations. Cancer Discov; 3(7); 742–50. ©2013 AACR. See related commentary by Nissan et al., p. 719 This article is highlighted in the In This Issue feature, p. 705
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, KRAS or BRAF mutant CRC usually develops resistance to MEK inhibitors [25,163].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [25]
In the citing paper
“SCH772984, a novel ERK inhibitor, effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor resistance models and reversed the sensitivity of including CRC to BRAF and MEK inhibitors [25].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [25]
In the citing paper
“preclinical studies suggest that it may be related to the reactivation of the ERK signaling pathway [25].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [25]
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“5 Introduction Specific inhibitors of RAF and MEK kinases have been developed to target BRAF and RAS mutant tumors (1-6).”
BackgroundHauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989 · cited 1×
“5 Introduction Specific inhibitors of RAF and MEK kinases have been developed to target BRAF and RAS mutant tumors (1-6).”
BackgroundCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810 · cited 3×
“5 Introduction Specific inhibitors of RAF and MEK kinases have been developed to target BRAF and RAS mutant tumors (1-6).”
BackgroundImproved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160 · cited 1×
“5 Introduction Specific inhibitors of RAF and MEK kinases have been developed to target BRAF and RAS mutant tumors (1-6).”
BackgroundRAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 3×
“3C ), consistent with previously described alleles that confer AZD6244 resistance ( 17 ).”
BackgroundImproved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022 · cited 1×
“It certain contexts, it has been demonstrated that RAF inhibitor efficacy can be limited by ERK reactivation that occurs within 24 hours (22).”
BackgroundDissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005 · cited 1×
“Importantly, BRAF amplification has been demonstrated to mediate cross-resistance to MEK inhibitors (10) while MEK mutations mediate cross-resistance to BRAF inhibitors (17, 20).”
BackgroundShi, H., Moriceau, G., Kong, X., Lee, M.-K., Lee, H., Koya, R. C., Ng, C., Chodon, T., Scolyer, R. A., Dahlman, K. B., et al. (2012) · Nature Communications · doi:10.1038/ncomms1727 · Cited by 640 · cited 5×
“BRAF amplification, as well as expression of drug resistant BRAF splice-variants lacking N-terminal regulatory regions, have been described as clinical resistance mechanisms in PLX4032-relapsed melanoma patients while MEK1 was identified in a patient who relapsed on treatment with the MEK inhibitor AZD6244 (10, 17-19).”
BackgroundInfluentialMEK1 mutations confer resistance to MEK and B-RAF inhibition
Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 633 · cited 6×
“BRAF amplification, as well as expression of drug resistant BRAF splice-variants lacking N-terminal regulatory regions, have been described as clinical resistance mechanisms in PLX4032-relapsed melanoma patients while MEK1 was identified in a patient who relapsed on treatment with the MEK inhibitor AZD6244 (10, 17-19).”
BackgroundResultInfluential
Research works printed but not linked: 1
- Flaherty, 2011, Vemurafenib, Nat Rev, 10, 811
Cited by
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471
“The reason for this difference is unclear, although ERK 462 inhibitors have demonstrated activity in cells with acquired BRAF and MEK inhibitor463 resistance [61].”
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Self-citationRAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.008 · Cited by 996
“Moreover, MAPK pathway inhibitors including selective MEK and ERK inhibitors are also under active clinical evaluation in patients with breast and other cancer types (Flaherty et al., 2012; Morris et al., 2013).”
Background
Metadata
- Authors
- Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., Long, B., Liu, J., DiNunzio, E., Windsor, W., Zhang, R., Zhao, S., Angagaw, M. H., Pinheiro, E. M., Desai, J., Xiao, L., Shipps, G., Hruza, A., Wang, J., Kelly, J., Paliwal, S., Gao, X., Babu, B. S., Zhu, L., Daublain, P., Zhang, L., Lutterbach, B. A., Pelletier, M. R., Philippar, U., Siliphaivanh, P., Witter, D., Kirschmeier, P., Bishop, W. R., Hicklin, D., Gilliland, D. G., Jayaraman, L., Zawel, L., Fawell, S., & Samatar, A. A.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Samatar, Ahmed A.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2013-07-01
- Volume
- 3
- Issue
- 7
- Pages
- 742-750
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2116386978
- Cited by
- 676
- References
- 25
- Citations by year
- 2026: 31 · 2025: 32 · 2024: 53 · 2023: 40 · 2022: 55 · 2021: 69 · 2020: 56 · 2019: 63 · 2018: 58 · 2017: 53 · 2016: 52 · 2015: 45 · 2014: 52 · 2013: 17
- FWCI
- 25.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- SCH772984, MAPK signaling, BRAF inhibitor resistance, MEK inhibitor resistance, melanoma, RAS mutations, KRAS, NRAS, drug resistance, xenograft models, anticancer activity
- MeSH terms
- Humans, Mutation, Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, MAP Kinase Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-0070
- The paper
- Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., Long, B., Liu, J., DiNunzio, E., Windsor, W., Zhang, R., Zhao, S., Angagaw, M. H., Pinheiro, E. M., Desai, J., . . . Samatar, A. A. (2013). Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-0070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.